Results 91 to 100 of about 127,252 (263)
Journal of Medical Case Reports, 2012 Introduction There are limited treatment options for people with schizophrenia with cytochrome P450 2D6 ultrarapid metabolizer status who do not respond to amisulpride.
Gahr Maximilian +4 more
doaj +1 more source
Deep Recurrent Neural Network for Protein Function Prediction from Sequence [PDF]
arXiv, 2017 As high-throughput biological sequencing becomes faster and cheaper, the need to extract useful information from sequencing becomes ever more paramount, often limited by low-throughput experimental characterizations. For proteins, accurate prediction of their functions directly from their primary amino-acid sequences has been a long standing challenge.
arxiv
Molecular and cellular paradigms of multidrug resistance in cancer
Cancer Reports, Volume 5, Issue 12, December 2022., 2022 Abstract Background The acquisition of resistance to chemotherapy is a major hurdle in the successful application of cancer therapy. Several anticancer approaches, including chemotherapies, radiotherapy, surgery and targeted therapies are being employed for the treatment of cancer.
Foram U. Vaidya +6 more
wiley +1 more source
mBio, 2016 Ergosterol is a major and specific component of the fungal plasma membrane, and thus, the cytochrome P450 enzymes (Erg proteins) that catalyze ergosterol synthesis have been selected as valuable targets of azole antifungals.
Jinxing Song +7 more
doaj +1 more source
Cytochrome P450-Activated Prodrugs [PDF]
Future Medicinal Chemistry, 2013 A prodrug is a compound that has negligible, or lower, activity against a specified pharmacological target than one of its major metabolites. Prodrugs can be used to improve drug delivery or pharmacokinetics, to decrease toxicity, or to target the drug to specific cells or tissues.
openaire +3 more sources
Vascular co‐option and vasculogenic mimicry mediate resistance to antiangiogenic strategies
Cancer Reports, Volume 5, Issue 12, December 2022., 2022 Abstract Background The concept that all the tumors need the formation of new vessels to grow inspired the hypothesis that inhibition of angiogenesis would have led to “cure” cancer. The expectancy that this type of therapy would have avoided the insurgence of resistance was based on the concept that targeting normal vessels, instead of the cancer ...
Francesco Pezzella, Domenico Ribatti
wiley +1 more source
Acta Pharmaceutica Sinica B, 2012 Cytochrome P450 (CYP)-mediated epoxidation of arachidonic acid (AA) contributes to important biological functions, including the pain-relieving responses produced by analgesic drugs. However, the relevant epoxygenase(s) remain unidentified. Presently, we
Jun Yang +4 more
doaj +1 more source
Clinical Pharmacology in Drug Development, Volume 12, Issue 1, Page 30-37, January 2023., 2023 Abstract The bioequivalence of a generic fudosteine tablet vs a brand‐named fudosteine tablet under fasting and fed conditions was evaluated in this study. This randomized, open‐label, single‐dose, 4‐way replicate, crossover, bioequivalence study included 64 healthy Chinese subjects (fasting cohort, n = 32; fed cohort, n = 32) who were assigned to ...
Mingxue Zhu +6 more
wiley +1 more source
An Update: Enzymatic Synthesis for Industrial Applications
Angewandte Chemie International Edition, Accepted Article.Supported by rapid technological advancements, biocatalytic applications have matured into a sustainable, scalable, and cost‐competitive alternatives to established chemical catalysis. This review presents the most recent examples of enzyme‐based solutions for the manufacturing of molecules with extended carbon‐carbon frameworks and multiple ...
Thomas Bayer +4 more
wiley +1 more source
Clinical Pharmacology in Drug Development, Volume 12, Issue 1, Page 94-106, January 2023., 2023 Abstract Deutetrabenazine (Austedo) is indicated in adults for chorea associated with Huntington disease and tardive dyskinesia. Escalating deutetrabenazine doses were administered to healthy volunteers who were cytochrome P450 2D6 extensive/intermediate metabolizers (EMs) or poor metabolizers (PMs) to determine pharmacokinetic exposure of parent drug ...
Frank Schneider +7 more
wiley +1 more source